Follow The Filings

SCYX Scynexis Inc.

Health Care, filed as SCYNEXIS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 exits

In 2026 Q2 David Witzke and Nathan Fischel sold out of Scynexis.

Who owns SCYX

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management exited 2026 Q2 Last 2026 Q1 0.44% Exit −0.44% 2,081,660 $1.9M History
Nathan Fischel, Dafna Capital Management exited 2026 Q2 Last 2026 Q1 0.23% Exit −0.23% 1,086,956 $997K History

0 current, 2 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by SCYX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SCYX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Gonzalez David Angulo CEO
    Buy
    — 108,695 shares +8.7% to stake
    Traded Apr 1 Filed Apr 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 9 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.02,8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.03,5.07,8.01,9.01 Filing Doc
8-K 5.03,9.01 Filing Doc
8-K 5.07,8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
424B3 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.01,7.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $140.14M $3.75M $20.6M
Net income $67.04M -$21.29M -$8.61M
Net margin * 47.8% -568.3% -41.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $102.12M $72.18M $40.37M
Total non-current assets * $26.3M $18.46M $18.65M
Total assets $128.41M $90.64M $59.03M
Total current liabilities $16.3M $24.1M $5.73M
Total non-current liabilities * $39.15M $11.47M $3.92M
Total equity $72.96M $55.08M $49.38M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $60.16M -$24.01M -$5.28M
Cash from investing -$34.88M $6.15M $24.31M
Cash from financing -$36.72M -$0.139M -$14.17M
Net change in cash * -$11.44M -$18M $4.85M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.